Ider Cerutti
Grupo México
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ider Cerutti.
Clinical Lymphoma, Myeloma & Leukemia | 2010
Santiago Pavlovsky; Claudia Corrado; Miguel A. Pavlovsky; Maria Virginia Prates; Lucia Zoppegno; Mario Giunta; Ider Cerutti; Elsa Palomino; Fernando Pagani; Francisco Lastiri; Daniel Bär; Raimundo Fernando Bezares; Graciela Avila
BACKGROUND Doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) plus involved-field radiation therapy (IFRT) is the gold-standard treatment for early and advanced stages of Hodgkin lymphoma (HL). We evaluated the outcomes of patients according to prognosis at diagnosis and over time to determine who achieved complete remission (CR). PATIENTS AND METHODS Treatment-naive patients under the age of 75 years at all stages of HL were eligible. The favorable group (FG) contained patients with stage IA-IIIA disease without bulky areas who achieved CR after the third cycle of ABVD. They received only IFRT at 25 Gy. Patients in the unfavorable group (UG) exhibited stages IIIB and IV HL. The UG also included all patients with bulky disease and the subset of the FG without CR after 3 cycles of ABVD, ie, slow responders (FGSR). The UG received 6 cycles of ABVD plus IFRT at 30 Gy to bulky areas at diagnosis or to those areas remaining positive after the third cycle of ABVD. RESULTS In total, 584 patients were evaluable: 285 of them belonged to the FG, and 299 to the UG. Rates of CR were 98% and 85% for the FG and the UG, respectively (P < .001). Sixty patients in the FG received 6 cycles of ABVD because they had not achieved CR after 3 cycles (ie, the FGSR subgroup). The 5-year event-free survival rate was 89% for the FG, 66% for the FGSR, and 72% for the UG (P < .001). The overall survival at 5 years was significantly better for the FG (98%) than for the FGSR (87%) and the UG (88%; P < .001). CONCLUSION Patients from the FG demonstrated excellent outcomes compared with those from the FGSR and UG, despite receiving less chemotherapy and fewer doses of IFRT.
Hematological Oncology | 2017
E. Ciliberti; Isolda Fernandez; Nicolas Matias Kurgansky; Virginia Prates; Lucia Zoppegno; P. Negri; Gustavo Milone; Ider Cerutti; S. Zabaljauregui; R. Mariano; H. Fernandez Grecco; Silvia Saba; F. Sackmann; Vanesa Castano; Guillermina Remaggi; María Cabrejo; Silvia Rudoy; E. Roveri; V. Cabane; C. Gumpel; Rossana L. Taus; M. Casale; F. Sakamoto; Astrid Pavlovsky
tomography (PET) is in the medium and long‐term follow‐up after complete response of Hodgkin lymphoma (HL) and aggressive non‐Hodgkin lymphoma (NHL) with mediastinal involvement at diagnosis. The aim of this study was to verify the reliability of positive PET scans of the mediastinum in following up patients with mediastinal lymphoma, using histological findings as comparison (gold standard). Methods: From January 2002 to February 2016, 483 patients with mediastinal lymphoma were followed after the end of front‐line treatment. Ninety‐six patients with a positive PET scan of the mediastinum underwent computed tomography scanning and surgical biopsy. Results: For 67 HL and 29 NHL, a suspicion of lymphoma relapse was raised based on positive mediastinal PET scanning. Histology confirmed relapse in 63 (48 HL and 15 NHL) of 96 patients (65.6%). In the remaining 33 (34,4%) cases, biopsy revealed: necrotic tissue in 7 patients, fibrosis in 7 patients, thymus in 7 patients, sarcoidosis in 4 patients, tuberculous granulomas in 2 patients, sarcoid‐like lymph node granulomatosis in 1 patient, tuberculosis lymph node granulomatosis in 1 patient, reactive inflammation lymph node in 3 patients, and thymoma in 1 patient. The maximum standardized uptake value was significantly higher among patients who had signs of relapse (63 true positive cases) than among those who stayed in remission (33 false positive cases), the median values being 10.30 (range, 3.2‐25.0) and 5.0 (range, 2.8‐12.6) respectively (P < .05). Conclusions: The analysis on this large series of 96 patients confirms the concept that patients with positive PET in the mediastinum during the follow‐up cannot be considered sufficient for final diagnostic purposes considering that at least one third of the patients can present only benign or, anyway, unrelated neoplastic pictures. Histological confirmation can be safely obtained by various biopsy techniques, the choice of which should be made on the basis of the clinical and imaging study findings case by case.
Annals of Oncology | 1996
Santiago Pavlovsky; B. Koziner; Gustavo Milone; F. Lastiri; R. Bayo; Isolda Fernandez; C. Dengra; J. Martinez Rolón; Leonardo Feldman; Gustavo Kusminsky; Claudia Corrado; E. Bullorsky; Jorge Milone; Juan Jose Garcia; Ider Cerutti; G. Saporito; A. Robinson; C. Canepa
Blood | 2010
Santiago Pavlovsky; Astrid Pavlovsky; Isolda Fernandez; Miguel A. Pavlovsky; Virginia Prates; Lucia Zoppegno; Ana Lisa Basquiera; Ider Cerutti; Andrea Rodríguez; Gustavo Milone; Vanesa Castano; Silvia Rudoy; Federico Sackmann; Lourdes Valles; Francisco Lastiri
Blood | 2017
Florencia Negri Aranguren; Santiago Cranco; Claudia Shanley; Isolda Fernandez; Maria Virginia Prates; Victoria Otero; Lorena Fiad; Maria Cecilia Foncuberta; Marcela Miodosky; Miguel A. Pavlovsky; Gustavo Kuminsky; Javier Bordone; Bruno Wannesson; Ariel Corso Corso; Dardo Riveros; Marisa Marquez; Gustavo Jarchum; Maria Sol Jarchum; Ider Cerutti; Alicia Bistmas; Monica Tamashiro; Giselda De Stefano; Alicia Navieckas; Silvana Cugliari; Pedro Negri Aranguren; Gabriela Balaguer; Maria Tosin; Guillermina Remaggi; Juan Altuve; Juan José García García
Blood | 2017
Esteban Ciliberti; Isolda Fernandez; Maria Virginia Prates; Pedro Negri Aranguren; Gustavo Milone; Nicolas Matias Kurgansky; Lucia Zoppegno; Federico Sackman; Ider Cerutti; Soledad Zabaljauregui; Romina Mariano; Horacio Fernández Grecco; Silvia Saba; Guillermina Remaggi; María Cabrejo; Silvia Rudoy; Vanesa Castano; Eriberto Antonio Roveri; Rossana L. Taus; Carina Gumpel; Juan Francisco Sakamoto; Astrid Pavlovsky
Blood | 2008
Santiago Pavlovsky; Claudia Corrado; Miguel A. Pavlovsky; Virginia Prates; Lucia Zoppegno; Mario Giunta; Ider Cerutti; Elsa Palomino; Graciela Avila; Francisco Lastiri
Blood | 2008
Astrid Pavlovsky; Santiago Pavlovsky; Isolda Fernandez; Lucia Zoppegno; Ider Cerutti; Miguel A. Pavlovsky; Virginia Prates; Ana Basquiera; Claudia Corrado; Gustavo Milone; María Cabrejo; Horacio Fernández Grecco; Graciela Avila; Viviana Flores Dutrus; Karina Gumpel; Vanina Cabanne; Silvia Saba; Francisco Lastiri
Blood | 2006
Santiago Pavlovsky; Claudia Corrado; Miguel A. Pavlovsky; Virginia Prates; Lucia Zoppegno; Mario Giunta; Ider Cerutti; Elsa Palomino; Fernando Pagani; Francisco Lastiri; Maria C. Narbaitz; Fernando Cavagnaro; Graciela Avila
Blood | 2005
Jorge H. Milone; Javier Bordone; Gustavo Kusminsky; Cecilia Foncuberta; Juan Garcia; Juliana Martinez Rolon; Eduardo Bullorsky; Cristina Dengra; Ider Cerutti